Glycotope Gmbh

Max-delbruck-centrum Fur Molekulare Medizin

Glycotype Gmbh

Nemod Biotherapeutics Gmbh & Co. Kg

Uwe Karsten

Steffen Goletz

Antje Danielczyk

Renate Stahn

Peter Ravn

Peter Astrup Christensen

Hans Paulsen

Franz-Georg Hanisch

The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.

Recognition molecules for the treatment and detection of tumors

The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumors. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumors.

Method for the production of an immunostimulating mucin (MUC1)

The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.

Tumor-specific recognition molecules

The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.

MUC1 antibodies

The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising such recognition molecules, methods for the production of such recognition molecules, and to the use of such recognition molecules in the diagnosis and therapy of tumor diseases.

Tumor vaccines for the use against MUC1 positive carcinomas are presented. A tumor vaccine containing synthetic peptides comprising sequences of the human epithelial mucin MUC1 containing the immunodominat region PDTRPAP which is glycosylated at the threonine. Preferred glycosylation of the immunodominant region is a O-glycosidically linked a-N-acetylgalactosamine (GalNAc) or short chained oligosaccharides. The present invention can be used on all MUC1-positive carcinomas.

Growing community of inventors

Panketal, Germany

Uwe Karsten